Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

被引：10
|
作者：
Pipe, Steven W. [1 ]
Collins, Peter [2 ]
Dhalluin, Christophe [3 ]
Kenet, Gili [4 ,5 ]
Schmitt, Christophe [3 ]
Buri, Muriel [3 ]
Jimenez-Yuste, Victor [6 ]
Peyvandi, Flora [7 ,8 ,9 ]
Young, Guy [10 ]
Oldenburg, Johannes [11 ]
Mancuso, Maria Elisa [12 ]
Kiialainen, Anna [3 ]
Chang, Tiffany [13 ]
Lehle, Michaela [3 ]
Fijnvandraat, Karin [14 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Cardiff Univ, Sch Med, Cardiff, Wales
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] Sheba Med Ctr, Ramat Gan, Israel
[5] Tel Aviv Univ, Tel Aviv, Israel
[6] Univ Autonoma Madrid, La Paz Univ Hosp, Madrid, Spain
[7] Fdn IRCCS CaGranda Osped Maggiore Policlin, Angelo Bianchi Bon Hemophilia, Milan, Italy
[8] Thrombosis Ctr, Milan, Italy
[9] Univ Milan, Milan, Italy
[10] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA
[11] Univ Bonn, Bonn, Germany
[12] IRCCS Humanitas Res Hosp, Rozzano, Italy
[13] Spark Therapeut Inc, San Francisco, CA USA
[14] Univ Amsterdam, Amsterdam, Netherlands
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-157264
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Additional use of Factor VIII to a Patient with Severe Hemophilia a Receiving Emicizumab Prophylaxis from Infancy
    Yagi, Takeshi
    Matsuda, Takehiro
    Inamine, Itsuki
    Higa, Takeshi
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [22] A 5-Year Single-center Experience on the Use of Emicizumab Prophylaxis in Children With Severe Hemophilia A With and Without Factor VIII Inhibitors
    Hasan, Esraa Mohamed Ahmed
    Motwani, Jayashree
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2025, 47 (02) : e83 - e89
  • [23] Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial
    Reyes, Adriana
    Revir, Cedric
    Niggli, Markus
    Chebon, Sammy
    Schlagmueller, Simone
    Flacke, Jan-Paul
    Zortel, Max
    Paz-Priel, Ido
    Asikanius, Elina
    Hampton, Roger
    Mahajan, Anadi
    Schmidt, Elvira
    Edwards, Susan C.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (12) : 2079 - 2087
  • [24] Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
    Fredrik Jonsson
    Christophe Schmitt
    Claire Petry
    Francois Mercier
    Nicolas Frey
    Sylvie Retout
    Clinical Pharmacokinetics, 2021, 60 : 931 - 941
  • [25] Cost-Effectiveness of Emicizumab for Prophylaxis in People with Severe Hemophilia A without Inhibitors
    Decker-Palmer, Marquita
    Lin, Chia-Wei
    Wilson, Michele
    McDade, Cheryl
    Bawa, Komal
    Kowal, Stacey
    Ravelo, Arliene
    Yu, Elaine
    Ko, Richard H.
    BLOOD, 2022, 140 : 13041 - 13042
  • [26] Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors: 96-Week Interim Analysis of the AKATSUKI Study
    Nagao, Azusa
    Nogami, Keiji
    Suzuki, Nobuaki
    Nagae, Chiai
    Ando, Masahiko
    Kuwatsuka, Yachiyo
    Nosaka, Daisuke
    Kyogoku, Yui
    Shimura, Tomomi
    Matsushita, Tadashi
    BLOOD, 2024, 144 : 2588 - 2589
  • [27] Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
    Jonsson, Fredrik
    Schmitt, Christophe
    Petry, Claire
    Mercier, Francois
    Frey, Nicolas
    Retout, Sylvie
    CLINICAL PHARMACOKINETICS, 2021, 60 (07) : 931 - 941
  • [28] Three- Year Interim Analysis Results of the AOZORA Study to Evaluate the Long-Term Safety and Joint Health in Children with Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab
    Shima, Midori
    Takedani, Hideyuki
    Kitsukawa, Kaoru
    Taki, Masashi
    Ishiguro, Akira
    Nagae, Chiai
    Nagao, Azusa
    Nosaka, Daisuke
    Kyogoku, Yui
    Oki, Hiroki
    Iwasaki, Keisuke
    Nogami, Keiji
    BLOOD, 2023, 142
  • [29] Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy
    Shima, Midori
    Suzuki, Nobuaki
    Nishikii, Hidekazu
    Amano, Kagehiro
    Ogawa, Yoshiyuki
    Kobayashi, Ryota
    Ozaki, Ryoto
    Yoneyama, Koichiro
    Mizuno, Narumi
    Sakaida, Emiko
    Saito, Makoto
    Okamura, Takashi
    Ito, Toshihiro
    Hattori, Norimichi
    Higasa, Satoshi
    Seki, Yoshinobu
    Nogami, Keiji
    THROMBOSIS AND HAEMOSTASIS, 2024,
  • [30] Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies
    Mahlangu, Johnny
    Jimenez-Yuste, Victor
    Ventriglia, Giuliana
    Niggli, Markus
    Barlera, Simona
    Hermans, Cedric
    Lehle, Michaela
    Chowdary, Pratima
    Jew, Lyle
    Windyga, Jerzy
    Frenzel, Laurent
    Schmitt, Christophe
    Castaman, Giancarlo
    Pipe, Steven W.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (02)
12345